Diabetes drugs like Ozempic lower cancer risks: Study

A category of diabetes medicines, which embody the best-selling drug Ozempic, are related to a decreased danger of sure obesity-related cancers, based on a research launched Friday.

Revealed within the journal JAMA, the research in contrast sufferers with Kind 2 diabetes who had been handled with insulin versus sufferers who got a category of drug referred to as GLP-1 agonists, like Ozempic, between 2005 and 2018.

The researchers discovered that the sufferers who obtained GLP-1 agonists had a considerably decrease danger of growing 10 out of 13 cancers studied, together with kidney, pancreatic, esophageal, ovarian, liver and colorectal most cancers.

Among the many cancers which noticed no important change in danger had been thyroid most cancers and breast most cancers in postmenopausal ladies.

“Weight problems is well-known to be related to at the very least 13 most cancers sorts,” research creator Rong Xu mentioned in an e-mail to AFP.

“Our research offers proof that GLP-1RAs maintain promise in breaking the hyperlink between weight problems and most cancers,” Xu mentioned.

Among the many medicine studied had been semaglutide—commercially offered as Ozempic—in addition to liraglutide and others. Ozempic was accredited in america in 2017.

GLP-1 agonists have been round for about 20 years, however a brand new technology of those medicine, amongst them Ozempic, has been popularized for his or her extra important weight reduction results.

Xu urged that the protecting advantages demonstrated within the research could encourage medical doctors to prescribe GLP-1 therapies for diabetes sufferers as an alternative of different medicines like insulin.

© 2024 AFP